Overview

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Global Coalition for Adaptive Research

Collaborators:

Bayer
Kazia Therapeutics Limited
Kintara Therapeutics, Inc.

Treatments:

Dianhydrogalactitol
GDC-0084
Lomustine
Temozolomide